The upregulation of TGM2 is associated with poor prognosis and the shaping of the inflammatory tumor microenvironment in lung squamous cell carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tissue transglutaminase (TGM2) promotes lung squamous cell carcinoma (LUSC) progression by affecting cell proliferation and invasion. Targeting TGM2 offers a potential new therapeutic strategy for LUSC treatment.
Area Of Science
- Oncology
- Biochemistry
- Bioinformatics
Background
- Tissue transglutaminase (TGM2) is an enzyme involved in extracellular matrix formation.
- Its role in lung squamous cell carcinoma (LUSC) tumorigenesis requires further elucidation.
Purpose Of The Study
- To investigate the function and prognostic significance of TGM2 in LUSC.
- To explore TGM2's relationship with tumor-promoting inflammation and immunotherapy sensitivity.
Main Methods
- Comprehensive bioinformatics analysis of TGM2 expression in LUSC.
- In vitro experiments involving TGM2 overexpression and knockdown.
- Assessment of TGM2's impact on cancer cell proliferation, apoptosis, and invasion.
Main Results
- High TGM2 expression in LUSC correlates with poorer patient prognosis.
- Elevated TGM2 levels are linked to tumor-promoting inflammation and potentially increased immunotherapy sensitivity.
- TGM2 significantly influences LUSC cell proliferation, apoptosis, and invasion.
Conclusions
- TGM2 acts as a cancer-promoting factor in LUSC progression.
- Targeting TGM2 presents a promising therapeutic avenue for LUSC treatment.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...